Get the Stockscreener App
33.05
4.45%
-1.54
Supernus Pharmaceuticals Inc stock is traded at $33.05, with a volume of 755.25K.
It is down -4.45% in the last 24 hours and down -14.33% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$34.59
Open:
$34.74
24h Volume:
755.25K
Relative Volume:
2.08
Market Cap:
$1.82B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
30.90
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
-15.49%
1M Performance:
-14.33%
6M Performance:
-4.73%
1Y Performance:
+17.45%
1-Day Range:
$32.98
$34.87
1-Week Range:
$32.53
$39.99
52-Week Range:
$25.53
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
33.05 | 1.82B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
New York State Teachers Retirement System Boosts Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus plunges as mid-stage trial for depression therapy fails - MSN
Supernus' depression treatment fails mid-stage trial, shares plunge - MSN
Depression failure sends Supernus shares downwards - The Pharma Letter
How the (SUPN) price action is used to our Advantage - Stock Traders Daily
Supernus phase IIb results drag down the stock - BioWorld Online
Cantor Fitzgerald cuts Supernus stock rating, target to $36 By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial - AOL
Supernus’s stock sinks after depression drug fails trial - Yahoo
Sanofi reaches consumer health deal; Supernus antidepressant fails study - BioPharma Dive
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & ... - The Bakersfield Californian
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; - GlobeNewswire
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsSUPN - ACCESS Newswire
Supernus stock falls after trial setback (update) (SUPN:NASDAQ) - Seeking Alpha
Supernus reports less than super data for depression drug - pharmaphorum
Supernus Plunges On Failed Phase 2b Study Of SPN-820 In Treatment-resistant Depression - Nasdaq
Supernus Pharma sinks after depression drug fails mid-stage trial goal - TradingView
Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint - Marketscreener.com
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression - GlobeNewswire
Supernus Announces Topline Results From Phase 2B Study In Adults With Treatment Resistant Depression - Marketscreener.com
Supernus' depression treatment fails mid-stage trial, shares plunge -February 18, 2025 at 04:49 pm EST - Marketscreener.com
Supernus' depression treatment fails mid-stage trial -February 18, 2025 at 04:35 pm EST - Marketscreener.com
Supernus Pharma stock tumbles after failed depression study By Investing.com - Investing.com Nigeria
Supernus Pharma stock tumbles after failed depression study - Investing.com India
Clinical Trial Setback: Supernus Depression Treatment Shows No Advantage Over Placebo - StockTitan
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57 - Marketscreener.com
Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Yousif Capital Management LLC Sells 425 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Armenian Reporter
41,426 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Empowered Funds LLC - Defense World
Yousif Capital Management LLC Has $768,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Access to Parkinson’s medication likely by summer: Supernus official - Parkinson's News Today
Janney Montgomery Scott LLC Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Stephens Investment Management Group LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Supernus Pharmaceuticals to Host Conference Call and - GlobeNewswire
Supernus Q4 Earnings: CEO and CFO Set to Unveil Full Year Performance Metrics - StockTitan
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking - Simply Wall St
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells 9,477 Shares of Stock - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year HighHere's Why - MarketBeat
Supernus wins FDA approval for Parkinson’s pump on fourth try - MSN
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight - The Globe and Mail
Supernus: New Approval Holds Promise Of Increased Growth (SUPN) - Seeking Alpha
US FDA approves Supernus' drug-device combination for Parkinson's disease - MSN
Top Supernus Executive Offloads Significant Stock Holdings! - TipRanks
Supernus Pharmaceuticals exec sells shares worth $376,236 By Investing.com - Investing.com Australia
Supernus Pharmaceuticals exec sells shares worth $376,236 - MSN
FDA nod at last for Supernus’ Parkinson’s infusion therapy - The Pharma Letter
Stifel maintains hold on Supernus, price target at $38 - MSN
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease - GlobeNewswire
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 27 '25 |
Option Exercise |
29.61 |
2,573 |
76,187 |
12,722 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 28 '25 |
Option Exercise |
29.61 |
700 |
20,727 |
10,849 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 27 '25 |
Sale |
39.62 |
2,573 |
101,942 |
10,149 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 28 '25 |
Sale |
39.62 |
700 |
27,734 |
10,149 |
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):